Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Bloomberg

Duke's Harvey on Why SpaceX's IPO Could Distort Passive Flows

Shares of SpaceX appear ready to jump when they start trading on Friday after Elon Musk's company made history with a $75 billion IPO that instantly turned it into one of the biggest public companies in the world. Early indications of buying interest on Nasdaq pointed to a roughly 30% jump from the shares' offering price of $135. The stock is expected to officially start trading later Friday under the ticker SPCX. Campbell Harvey, Professor of Finance at Duke University's Fuqua School of Business, breaks down why the SpaceX IPO could expose major flaws in index construction, passive fund buying and market structure, with a tiny float and accelerated benchmark inclusion set to intensify demand.

Leia mais: Duke's Harvey on Why SpaceX's IPO Could Distort Passive Flows
Bloomberg

Half of Hormuz Stoppages Restored, US Energy Chief Says

US Energy Secretary Chris Wright said roughly 7 million barrels of daily oil and fuel shipments are flowing through the Strait of Hormuz, or about half of the volumes stranded at the start of the Iran war. Wright spoke Friday with Annmarie Hordern during the Bloomberg Energy Security Executive Briefing in Houston.

Leia mais: Half of Hormuz Stoppages Restored, US Energy Chief Says
Bloomberg

HSBC's Kettner: Stocks Don't Need a Catalyst to Keep Rising

Stocks can continue climbing without a specific catalyst, despite recent volatility, as structural factors support higher valuations, according to HSBC Chief multi-asset strategist Max Kettner. "I don't think there needs to be a catalyst," said Kettner. He explained that we're in a world of structurally higher nominal growth, and structurally higher revenue growth, meaning if company margins don't change then earnings will continue to rise. Kettner joined Guy Johnson, Anna Edwards and Tom Mackenzie on "The Opening Trade."

Leia mais: HSBC's Kettner: Stocks Don't Need a Catalyst to Keep Rising
Grafa

Cogent Biosciences presents preclinical data for best-in-class contender CGT1145 at EHA 2026

Cogent Biosciences (NASDAQ:COGT) unveiled highly supportive preclinical findings for its novel small molecule therapeutic candidate, CGT1145, at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

Leia mais: Cogent Biosciences presents preclinical data for best-in-class contender CGT1145 at EHA 2026